Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02834078
Other study ID # HD/150301/BGG/PD
Secondary ID
Status Completed
Phase N/A
First received July 6, 2016
Last updated July 12, 2016
Start date September 2015
Est. completion date July 2016

Study information

Verified date July 2016
Source Vedic Lifesciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority India: Central Drugs Standard Control Organization
Study type Interventional

Clinical Trial Summary

According to the International Diabetes Federation, one in every 12 individuals is a diabetic (about 8% of the world population). Major risk factors of diabetes are all the aspects of modern life which include obesity, over-weight, high-risk behavior like smoking, alcohol, multiple drug use-recreational or prescribed, environmental risk factors like inactivity and lack of exercise. However there is a window of opportunity between health and disease, which is pre-diabetes.

Pre-diabetes has been defined by American Diabetes Association as Impaired Glucose Tolerance (IGT) which is 7.8 -11.0 mmol/l, Impaired Fasting Glucose Test (IFT) which is 5.6-6.9mmol/l and now added Glycosylated Hemoglobin (HbA1c) of 5.7% to 6.4%.

Though there are plenty of drugs available for significantly impaired glucose metabolism (including oral hypoglycemic agents and insulin), their use in marginally impaired glucose metabolism is questionable due to risk of untoward hypoglycemia.

On the other hand, herbal products like curcumin, as a single ingredient has poor bioavailability problem that restricts its use as standalone treatment. Inulin works as pre-biotic and help to maintain gut microbiota which is considered as precursor for progress of prediabetes to diabetes. However, it does not have any role in primary pathophysiology of impaired glucose metabolism, i.e. pancreatic β cell dysfunction, insulin resistance, hepatic gluconeogenesis or intestinal glucose absorption. Resveratrol and omega-3 basically work on anti-oxidant pathways.

None of these popular ingredients has been studied for their role in structural and functional health of pancreatic β cells which is very important for prediction of further progress of marginally impaired glucose metabolism to significantly impaired glucose metabolism.

It is an unmet need to develop a product which not only improves insulin sensitivity, but also help to preserve the structural and functional health of pancreatic β cells. It also needs to improve overall metabolic and endothelial health of the person considering the close association between impaired glucose metabolism and these parameters.

The proposed supplement - "Berberine GlucoGold "- is an improved version of successfully marketed supplement - Berberine GlucoDefense. It has a balanced composition in which all the ingredients complement each other in such a way that along with the individual role in glucose metabolism it also takes care of overall bioavailability and stability of the supplement. As per the previous data on ingredients, the supplement is also expected to preserve the structural and functional health of pancreatic β cells. The ingredients are also known to have positive effect on overall metabolic and endothelial health. Thus BGG has been developed to address the unmet needs in the area of glucose metabolism and overall metabolic health.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- Able and willing to provide informed consent.

- Treatment naïve male-female aged 20-60 years of age.

- BMI = 25 kg/m²

- Oral glucose tolerance test (OGTT) =140 and =250 mg/dl (pre-diabetes and early diagnosed diabetes within 45 days of diagnosis)

- Patient with chronic stable illness can be included ONLY IF he/she is currently NOT on any of the medications included in prohibited list of medicines.

- Currently on herbal supplements can be included after a wash-out period of 7 days.

- Subjects willing to abstain from nicotine and alcohol in the duration of the study.

Exclusion Criteria:

- Subjects with OGTT<140 mg/dl or = 250 mg/dl

- Current treatment with diabetes medications, including metformin

- Current treatment with glucocorticoids

- History of clinically significant hematological, hepatic or renal diseases, as per investigator discretion

- Uncontrolled chronic disease

- Hormonal Disorders

- Subjects on Steroids

- Subjects on Statins

- Chronic inflammatory diseases requiring any medication

- Migraine, Sinusitis

- Subjects Consuming NSAIDS for long term

- Medications include the drugs of prohibited range.

- Pregnant and lactating females.

- Subjects addicted to nicotine, alcohol or any other recreational drug.

- Subjects who are planning to fast for more than 4 days/ per month during the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Dietary Supplement:
BGG

Other:
Placebo


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Vedic Lifesciences Pvt. Ltd. Healthy Directions, LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Oral Disposition Index Day 0, Day 28, Day 56 and Day 84 No
Primary Change in Glycated hemoglobin Day 0, Day 28, Day 56 and Day 84 No
Secondary Change in Fasting blood sugar Day 0, Day 28, Day 56 and Day 84 No
Secondary Change in Body Mass Index Day 0, Day 28, Day 56 and Day 84 No
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Completed NCT03714646 - Beta Glucan and Acetate Production N/A
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT03480022 - Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS Phase 3
Active, not recruiting NCT05290233 - Time Restricted Eating Plus Exercise for Weight Management N/A
Withdrawn NCT05726409 - Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes N/A
Completed NCT04902326 - Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change) N/A
Recruiting NCT04168372 - Fructose: Substrate, Stimulus, or Both? N/A
Completed NCT03272074 - Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes N/A
Not yet recruiting NCT05939349 - A Prescription for Health Equity: A Healthcare Provider-based Produce Prescription Program for People With Prediabetes and Type 2 Diabetes N/A
Completed NCT04978376 - TRE With Physical Activity for Weight Management N/A
Recruiting NCT03997656 - A Digital Therapy for Diabetes Prevention Among Overweight Adults in Terengganu, Malaysia N/A
Recruiting NCT05166785 - BRInging the Diabetes Prevention Program to GEriatric Populations N/A
Completed NCT01729078 - Dietary Interventions in Prediabetes N/A
Completed NCT04507685 - Asian Indian Prediabetes Study N/A
Completed NCT03292315 - Once Weekly GLP-1 in Persons With Spinal Cord Injury Phase 4
Active, not recruiting NCT05353790 - Dietary Exchanges With Avocado and Mango in Pre-diabetes N/A
Active, not recruiting NCT03804892 - Can Brisk Walking Combined With Ingestion of a Lipid-lowering Drug Improve Fat Metabolism in Muscle? N/A